{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T22:55:47Z","timestamp":1775775347044,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,2,7]],"date-time":"2014-02-07T00:00:00Z","timestamp":1391731200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s00198-013-2615-z","type":"journal-article","created":{"date-parts":[[2014,2,6]],"date-time":"2014-02-06T17:02:26Z","timestamp":1391706146000},"page":"1369-1378","source":"Crossref","is-referenced-by-count":29,"title":["Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study"],"prefix":"10.1007","volume":"25","author":[{"given":"P.","family":"Hadji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Kauka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ziller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Birkholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Baier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Muth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,2,7]]},"reference":[{"key":"2615_CR1","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/bjc.1990.58","volume":"61","author":"PF Bruning","year":"1990","unstructured":"Bruning PF, Pit MJ, de Jong-Bakker M, van den Ende A, Hart A, van Enk A (1990) Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer 61:308\u2013310","journal-title":"Br J Cancer"},{"key":"2615_CR2","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/jbmr.5650100704","volume":"10","author":"GE Fuleihan","year":"1995","unstructured":"Fuleihan GE, Testa MA, Angell JE, Porrino N, Leboff MS (1995) Reproducibility of DXA absorptiometry: a model for bone loss estimates. J Bone Miner Res 10:1004\u20131014","journal-title":"J Bone Miner Res"},{"key":"2615_CR3","first-page":"624","volume":"47","author":"VC Jordan","year":"1987","unstructured":"Jordan VC, Fritz NF, Tormey DC (1987) Endocrine effects of adjuvant chemotherapy and long-term tamoxifen administration on node-positive patients with breast cancer. Cancer Res 47:624\u2013630","journal-title":"Cancer Res"},{"key":"2615_CR4","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1089\/jwh.1.1999.8.949","volume":"8","author":"EE Lower","year":"1999","unstructured":"Lower EE, Blau R, Gazder P, Tummala R (1999) The risk of premature menopause induced by chemotherapy for early breast cancer. J Womens Health Gend Based Med 8:949\u2013954","journal-title":"J Womens Health Gend Based Med"},{"key":"2615_CR5","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1200\/JCO.1996.14.5.1718","volume":"14","author":"J Bines","year":"1996","unstructured":"Bines J, Oleske DM, Cobleigh MA (1996) Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 14:1718\u20131729","journal-title":"J Clin Oncol"},{"key":"2615_CR6","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1200\/JCO.1999.17.1.120","volume":"17","author":"PJ Goodwin","year":"1999","unstructured":"Goodwin PJ, Ennis M, Pritchard KI, McCready D, Koo J, Sidlofsky S, Trudeau M, Hood N, Redwood S (1999) Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis. J Clin Oncol 17:120\u2013129","journal-title":"J Clin Oncol"},{"key":"2615_CR7","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","volume":"19","author":"CL Shapiro","year":"2001","unstructured":"Shapiro CL, Manola J, Leboff M (2001) Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19:3306\u20133311","journal-title":"J Clin Oncol"},{"key":"2615_CR8","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1210\/jc.2004-1444","volume":"90","author":"H Fuleihan Gel","year":"2005","unstructured":"Fuleihan Gel H, Salamoun M, Mourad YA, Chehal A, Salem Z, Mahfoud Z, Shamseddine A (2005) Pamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trial. J Clin Endocrinol Metab 90:3209\u20133214","journal-title":"J Clin Endocrinol Metab"},{"key":"2615_CR9","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1016\/j.ejca.2009.09.026","volume":"45","author":"P Hadji","year":"2009","unstructured":"Hadji P, Ziller M, Maskow C, Albert U, Kalder M (2009) The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer. Eur J Cancer 45:3205\u20133212","journal-title":"Eur J Cancer"},{"key":"2615_CR10","doi-asserted-by":"crossref","unstructured":"Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kassmann H, Piswanger-Solkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlbock M, Jakesz R, Austrian Breast and Colorectal Cancer Study Group (2008) Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 9:840\u2013849","DOI":"10.1016\/S1470-2045(08)70204-3"},{"key":"2615_CR11","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/archinte.165.5.552","volume":"165","author":"Z Chen","year":"2005","unstructured":"Chen Z, Maricic M, Bassford TL, Pettinger M, Ritenbaugh C, Lopez AM, Barad DH, Gass M, Leboff MS (2005) Fracture risk among breast cancer survivors: results from the Women\u2019s Health Initiative Observational Study. Arch Intern Med 165:552\u2013558","journal-title":"Arch Intern Med"},{"key":"2615_CR12","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jnci\/djr242","volume":"103","author":"E Amir","year":"2011","unstructured":"Amir E, Seruga B, Niraula S, Carlsson L, Oca\u00f1a A (2011) Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 103:1299\u20131309","journal-title":"J Natl Cancer Inst"},{"key":"2615_CR13","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.ctrv.2012.02.008","volume":"38","author":"P Hadji","year":"2012","unstructured":"Hadji P, Gnant M, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Guise TA, Lipton A, Aapro MS (2012) Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention? Cancer Treat Rev 38:798\u2013806","journal-title":"Cancer Treat Rev"},{"issue":"Suppl 1","key":"2615_CR14","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ctrv.2008.03.007","volume":"34","author":"DM Reid","year":"2008","unstructured":"Reid DM, Doughty J, Eastell R, Heys SD, Howell A, McCloskey EV, Powles T, Selby P, Coleman RE (2008) Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev 34(Suppl 1):S3\u2013S18","journal-title":"Cancer Treat Rev"},{"key":"2615_CR15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1053\/ctrv.2000.0212","volume":"27","author":"A Lipton","year":"2001","unstructured":"Lipton A, Costa L, Ali SM, Demers LM (2001) Bone markers in the management of metastatic bone disease. Cancer Treat Rev 27:181\u2013185","journal-title":"Cancer Treat Rev"},{"key":"2615_CR16","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1210\/jc.2009-1366","volume":"95","author":"DL Hershman","year":"2010","unstructured":"Hershman DL, McMahon DJ, Crew KD, Shao T, Cremers S, Brafman L, Awad D, Shane E (2010) Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment. J Clin Endocrinol Metab 95:559\u2013566","journal-title":"J Clin Endocrinol Metab"},{"key":"2615_CR17","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1093\/annonc\/mdr017","volume":"22","author":"P Hadji","year":"2011","unstructured":"Hadji P, Aapro MS, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Gnant M, Guise T, Lipton A (2011) Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 22:2546\u20132555","journal-title":"Ann Oncol"},{"key":"2615_CR18","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1200\/JCO.2008.16.4707","volume":"26","author":"DL Hershman","year":"2008","unstructured":"Hershman DL, McMahon DJ, Crew KD, Cremers S, Irani D, Cucchiara G, Brafman L, Shane E (2008) Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 26:4739\u20134745","journal-title":"J Clin Oncol"},{"key":"2615_CR19","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ejca.2010.11.024","volume":"47","author":"CL Shapiro","year":"2011","unstructured":"Shapiro CL, Halabi S, Hars V, Archer L, Weckstein D, Kirshner J, Sikov W, Winer E, Burstein HJ, Hudis C, Isaacs C, Schilsky R, Paskett E (2011) Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer 47:683\u2013689","journal-title":"Eur J Cancer"},{"key":"2615_CR20","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ctrv.2008.02.004","volume":"34","author":"MC Winter","year":"2008","unstructured":"Winter MC, Holen I, Coleman RE (2008) Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 34:453\u2013475","journal-title":"Cancer Treat Rev"},{"key":"2615_CR21","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","volume":"24","author":"R Coleman","year":"2013","unstructured":"Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, von Minckwitz G, Sleeboom HP, Forbes J, Barrios C, Frassoldati A, Campbell I, Paija O, Martin N, Modi A, Bundred N (2013) Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol 24:398\u2013405","journal-title":"Ann Oncol"},{"key":"2615_CR22","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","volume":"25","author":"A Brufsky","year":"2007","unstructured":"Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, Hohneker J, Lacerna L, Petrone S, Perez EA (2007) Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25:829\u2013836","journal-title":"J Clin Oncol"},{"key":"2615_CR23","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","volume":"365","author":"RE Coleman","year":"2011","unstructured":"Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Peterson J, Davies C, Hiley V, Gregory W, Bell R (2011) Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365:1396\u20131405","journal-title":"N Engl J Med"},{"key":"2615_CR24","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1470-2045(12)70226-7","volume":"13","author":"AH Paterson","year":"2012","unstructured":"Paterson AH, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, Weir LM, Brufsky AM, Dakhil S, Lad T, Baez-Diaz L, Gralow JR, Robidoux A, Perez EA, Zheng P, Geyer CE Jr, Swain SM, Costantino JP, Mamounas EP, Wolmark N (2012) Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol 13:734\u2013742","journal-title":"Lancet Oncol"},{"key":"2615_CR25","unstructured":"M\u00f6bus V, Diel IJ, Elling D, Harbeck N, Jackisch C, Thomssen C, Untch M, Conrad B, Schneeweiss A, Kreienberg R, Huober J, M\u00fcller V, L\u00fcck HJ, Bauerfeind I, Loibl S, Nekljudova V, von Minckwitz G (2011) GAIN study: a phase III trial to compare ETC. vs. EC-TX and ibandronate vs. observation in patients with node-positive primary breast cancer\u20141st interim efficacy analysis. Presented at: CTRC-AACR San Antonio Breast Cancer Symposium; 6\u201310 December 2011; San Antonio, TX. Abstract S2\u20134."},{"key":"2615_CR26","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","volume":"360","author":"M Gnant","year":"2009","unstructured":"Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rucklinger E, Greil R (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360:679\u2013691","journal-title":"N Engl J Med"},{"key":"2615_CR27","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/187152012799014913","volume":"12","author":"RT Chlebowski","year":"2012","unstructured":"Chlebowski RT, Col N (2012) Bisphosphonates and breast cancer prevention. Anticancer Agents Med Chem 12:144\u2013150","journal-title":"Anticancer Agents Med Chem"},{"key":"2615_CR28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3233\/BD-2010-0324","volume":"33","author":"RT Chlebowski","year":"2011","unstructured":"Chlebowski RT, Col N (2011) Bisphosphonates and breast cancer incidence and recurrence. Breast Dis 33:93\u2013101","journal-title":"Breast Dis"},{"key":"2615_CR29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31\u201341","journal-title":"Nephron"},{"key":"2615_CR30","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1200\/JCO.1997.15.4.1341","volume":"15","author":"T Saarto","year":"1997","unstructured":"Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I (1997) Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 15:1341\u20131347","journal-title":"J Clin Oncol"},{"key":"2615_CR31","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/90.9.704","volume":"90","author":"TJ Powles","year":"1998","unstructured":"Powles TJ, McCloskey E, Paterson AH, Ashley S, Tidy VA, Nevantaus A, Rosenqvist K, Kanis J (1998) Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst 90:704\u2013708","journal-title":"J Natl Cancer Inst"},{"key":"2615_CR32","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1200\/JCO.2008.19.1783","volume":"27","author":"SL Hines","year":"2009","unstructured":"Hines SL, Mincey BA, Sloan JA, Thomas SP, Chottiner E, Loprinzi CL, Carlson MD, Atherton PJ, Salim M, Perez EA (2009) Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol 27:1047\u20131053","journal-title":"J Clin Oncol"},{"key":"2615_CR33","unstructured":"Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Stoeger H, Dubsky PC, Jakesz R, Singer CF, Eidtmann H, Fesl C, Eiermann W, Greil R (2011) Significantly improved overall survival with adjuvant zoledronic acid in premenopausal breast cancer patients with endocrine-receptor-positive early breast cancer. Presented at: CTRC-AACR San Antonio Breast Cancer Symposium; 6\u201310 December 2011; San Antonio, TX. Abstract S1\u20132."},{"key":"2615_CR34","doi-asserted-by":"crossref","unstructured":"Marshall H, Gregory W, Bell R, Cameron DA, Dodwell DJ, Keane MM, Gil MJ, Davies C, Coleman RE (2012) Adjuvant therapy with zoledronic acid (AZURE-BIG 01\/04): the influence of menopausal status and age on treatment effects. J Clin Oncol 30(Suppl): Abstract 502.","DOI":"10.1200\/jco.2012.30.15_suppl.502"},{"key":"2615_CR35","doi-asserted-by":"crossref","unstructured":"Coleman RE, Rathbone EJ, Marshall HC, Wilson C, Brown JE, Gossiel F, Gregory WM, Cameron D, Bell R. (2012) Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study. Presented at: CTRC-AACR San Antonio Breast Cancer Symposium; 4\u20138 December 2012; San Antonio, TX. Abstract S6\u20134.","DOI":"10.1158\/0008-5472.SABCS12-S6-4"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-013-2615-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-013-2615-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-013-2615-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,15]],"date-time":"2020-08-15T04:27:11Z","timestamp":1597465631000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-013-2615-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,7]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["2615"],"URL":"https:\/\/doi.org\/10.1007\/s00198-013-2615-z","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,7]]}}}